Eversept Partners’s Edwards Lifesciences EW Stock Holding History

Eversept Partners’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-170,678	Closed	-$12.6M	–	64
2024 Q4	$12.6M	Buy	+170,678	New	+$11.9M	1.12%	21

Other funds holding EW

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Eversept Partners's EW Position: Q1 2025 in Review

Eversept Partners sold out of Edwards Lifesciences (EW) in Q1 2025, closing a stake of 170,678 shares — an estimated $12.6M sold.

Eversept Partners first reported a position in EW in Q4 2024 and held it in 1 quarter. The position peaked at $12.6M in Q4 2024. 1,205 funds tracked by Wall St. Rank hold EW as of Q1 2025.

Eversept Partners reported no remaining Edwards Lifesciences position as of Q1 2025 after selling out during the quarter.
Eversept Partners sold 170,678 Edwards Lifesciences shares in Q1 2025, an estimated $12.6M.
Eversept Partners first reported a position in Edwards Lifesciences in Q4 2024 and held it in 1 quarter.
Eversept Partners's Edwards Lifesciences position peaked at $12.6M in Q4 2024.
1,205 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q1 2025.

Based on Eversept Partners's 13F filing for Q1 2025, filed 15 May 2025.